87N Stock Chart & Stats
€13.10
€0.00(0.00%)
At close: 4:00 PM EST
€13.10
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€11.30 - €23.60
Previous CloseN/A
Volume0.00
Average Volume (3M)22.00
Market Cap
€4.72B
Enterprise Value€4.14K
Total Cash (Recent Filing)€112.73M
Total Debt (Recent Filing)€448.52M
Price to Earnings (P/E)33.9
Beta0.52
Next Earnings
Aug 04, 2026EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.51
Shares Outstanding49,709,717
10 Day Avg. Volume67
30 Day Avg. Volume22
Financial Highlights & Ratios
PEG Ratio2.50
Price to Book (P/B)3.15
Price to Sales (P/S)4.10
P/FCF Ratio218.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€19.98Price Target Upside52.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.53
Revenue Forecast (FY)€1.12B
Bulls Say, Bears Say
Bulls Say
Consistent Revenue Growth And BDS MomentumSustained top-line growth, driven by the Biopharmaceutical & Diagnostic Solutions (BDS) segment, indicates durable end-market demand for injectable packaging. Recurring supply relationships and regulatory qualification cycles make this revenue less cyclical and support multi‑year revenue visibility as biologics volumes expand.
Higher Mix Of High-Value Solutions & GLP‑1 ExposureA rising share of high-value products (cartridges, syringes, device assemblies) improves structural margin potential and customer stickiness. Deepening exposure to fast-growing GLP‑1 and biologics markets supports recurring, higher‑value program revenue and long-term demand diversification across premium product lines.
Capacity Expansion And U.S. Manufacturing Build-OutTargeted capex and line conversions are structural enablers to meet growing cartridge/syringe demand and reduce supply constraints. Localizing U.S. production and scaling Latina/Fishers increases customer qualification stickiness, shortens lead times, and supports long-term revenue capture despite near-term ramp costs.
Bears Say
Weak And Volatile Free Cash FlowNegative and inconsistent free cash flow reflects heavy growth capex and uneven cash conversion, limiting financial flexibility. Over the medium term this constrains the company's ability to self-fund expansion, reduce net debt, or return capital unless operating cash conversion improves as new capacity scales.
Engineering Segment Revenue Decline And Backlog RiskA sharp, persistent drop in Engineering revenue reduces diversification and creates execution/timing risk for recovery. Slower customer decision cycles and reliance on new orders mean revenue is sensitive to business development execution and could keep overall growth lumpy until backlog rebuilds.
Margin Pressure From Ramp-Related Depreciation And FX/TariffsCapacity ramp depreciation and persistent FX/tariff headwinds can structurally compress segment margins while volumes ramp. Until new lines reach utilization thresholds, elevated depreciation and external cost pressures may restrain margin scalability and cash conversion despite stronger adjusted EBITDA.
Stevanato Group News
87N FAQ
What was Stevanato Group Spa’s price range in the past 12 months?
Stevanato Group Spa lowest stock price was €11.30 and its highest was €23.60 in the past 12 months.
What is Stevanato Group Spa’s market cap?
Stevanato Group Spa’s market cap is €4.72B.
When is Stevanato Group Spa’s upcoming earnings report date?
Stevanato Group Spa’s upcoming earnings report date is Aug 04, 2026 which is in 8 days.
How were Stevanato Group Spa’s earnings last quarter?
Stevanato Group Spa released its earnings results on May 07, 2026. The company reported €0.11 earnings per share for the quarter, beating the consensus estimate of €0.103 by €0.007.
Is Stevanato Group Spa overvalued?
According to Wall Street analysts Stevanato Group Spa’s price is currently Undervalued.
Does Stevanato Group Spa pay dividends?
Stevanato Group Spa does not currently pay dividends.
What is Stevanato Group Spa’s EPS estimate?
Stevanato Group Spa’s EPS estimate is 0.13.
How many shares outstanding does Stevanato Group Spa have?
Stevanato Group Spa has 49,709,717 shares outstanding.
What happened to Stevanato Group Spa’s price movement after its last earnings report?
Stevanato Group Spa reported an EPS of €0.11 in its last earnings report, beating expectations of €0.103. Following the earnings report the stock price went down -5.627%.
Which hedge fund is a major shareholder of Stevanato Group Spa?
Currently, no hedge funds are holding shares in DE:87N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stevanato Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€19.98 (52.53% Upside)
€19.98 (52.53% Upside)
Blogger Sentiment
Bullish
DE:87N Sentiment 70%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth €178.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-29.33%
12-Months-Change
Fundamentals
Return on Equity
0.31%
Trailing 12-Months
Asset Growth
18.58%
Trailing 12-Months
Company Description
Stevanato Group Spa
Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Its core offerings span a wide array of products, including containment solutions, drug delivery systems, and medical devices, alongside diagnostic and analytical support. The company also produces specialized machinery for tasks such as visual inspection, assembly, packaging, and glass formation. Established in 1949, the company's main operations are situated in Piombino Dese, Italy, functioning as a subsidiary of Stevanato Holding S.R.L.
87N Company Deck
87N Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong top-line growth, robust Biopharmaceutical & Diagnostic Solutions momentum (notably syringes, biologics and GLP1 exposure), expanding high-value solution mix, margin expansion on an adjusted basis, and clear progress on strategic capacity investments. Offsetting these positives were a sharp revenue decline in the Engineering segment, segment-level gross margin compression for BDS driven by ramp-related depreciation, FX and tariff headwinds, a higher tax rate, modest free cash flow in the quarter due to heavy growth capex, and slower order conversion cycles in Engineering. Management reiterated full-year guidance and emphasized demand-driven capacity investment and operational optimization.View all DE:87N earnings summaries87N Stock 12 Month Forecast
Average Price Target
€19.98
▲(52.53% Upside)